Last reviewed · How we verify
NCT06695936
Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort Study
trial in Nasopharyngeal Carcinoma (NPC) in 329 participants. Not yet recruiting.
15 November 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 329 |
| Start date | 15 November 2024 |
| Primary completion | 15 November 2028 |
| Estimated completion | 20 November 2028 |
Conditions studied
- Nasopharyngeal Carcinoma (NPC) — all drugs for Nasopharyngeal Carcinoma (NPC) →
- Cognitive Function — all drugs for Cognitive Function →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 60, any sex, with Nasopharyngeal Carcinoma (NPC) or Cognitive Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational cohort study aimed at investigating changes in hippocampal function and its impact on cognitive function in newly diagnosed nasopharyngeal carcinoma patients without metastasis, from baseline to a period after radiotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06695936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Carcinoma (NPC)
Currently open trials in the same condition.
- NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
- NCT06796270 — Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma · NA · recruiting
- NCT07340515 — Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial · Phase 3 · recruiting
- NCT07328841 — Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinom · Phase 3 · recruiting
- NCT07101744 — Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure · Phase 2 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06695936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06695936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing